EntryPoint Capital’s Adaptive Biotechnologies ADPT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADPT
EntryPoint Capital's ADPT Position: Q2 2026 in Review
EntryPoint Capital sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 20,517 shares — an estimated $285K sold.
EntryPoint Capital first reported a position in ADPT in Q4 2023 and held it in 7 quarters. The position peaked at $480K in Q2 2024. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.
- EntryPoint Capital reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
- EntryPoint Capital sold 20,517 Adaptive Biotechnologies shares in Q2 2026, an estimated $285K.
- EntryPoint Capital first reported a position in Adaptive Biotechnologies in Q4 2023 and held it in 7 quarters.
- EntryPoint Capital's Adaptive Biotechnologies position peaked at $480K in Q2 2024.
- 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.